Sanofi: expanded collaboration with SK Bioscience

(CercleFinance.com) - Sanofi announces an extension of its collaboration with SK Bioscience to develop a new generation of pneumococcal conjugate vaccines, and the launch of a Phase III program for its VPC21 vaccine.


This 21-valent pneumococcal conjugate vaccine (VPC21) is the first conjugate vaccine candidate against more than 20 pneumococcal serotypes to be dedicated to a Phase III program in infants and young children", he points out.

Under the terms of the extended agreement, the two companies will co-finance R&D expenses. Sanofi will make an initial payment of 50 million euros to SK Bioscience, followed by milestone payments on development and commercialization targets.

Once the vaccine is licensed, Sanofi will take charge of its commercialization worldwide, with the exception of South Korea, where SK Bioscience will have exclusive sales rights. SK Bioscience will also receive royalties on sales outside South Korea.

Copyright (c) 2024 CercleFinance.com. All rights reserved.